Project Management for Generics

Place
Valletta, St. Julians, Malta
Site visit
Dates
11 - 13 May 2020
Who should attend?

Senior management, Project Managers, Strategic planners, Business development, Portfolio planners, R&D Managers, Regulatory Affairs

Summary

This three-day course presents a unique blend of soft and hard skills that go to make successful project management with particular reference to the generic pharmaceutical industry. The participants will learn and understand; What makes a successful project, How to construct a project plan, Implementation monitoring and closing out, Managing the project and managing the people, Detailed analysis of Planning in the Generics industry and Critical path analysis.

Aims

Delegates will explore & understand:

  • Differentiation between targets and strategy, how to prepare the business case
  • Alignment to the strategic business objectives
  • Regulatory requirements for PM process documentation
  • How cultural clash can cause projects to fail & how to prevent such failures
  • Methods of estimating project management risk
  • Role of business analyst in a risk management process

Key Topics

  • Best practices in project portfolio management
  • Preparing the business case and the project charter
  • Project case financing & Business process management
  • Stakeholders analysis, Matrix management structures
  • Managing multiple projects, PM in outsourcing
  • Linking in-licensing, projects and portfolio management
  • Planning in the Generics industry
  • Risk assessment in pharmaceutical development
  • Project Closure and Post-Closure Issues
  • PM process documentation vs Regulatory requirements

Programme

All training materials will be provided in printed and digital form

All delegates will receive printed and LinkedIn certificates

• Critical discussions will include how to make sure that the project plan is aligned to the strategy of the company

• As many companies are involved in cross-border mergers and acquisitions it is necessary to look at the cultural differences and how these can affect communication and deliverables.

• Understanding of project risk management essential for project control. This course will be of great value to you in identifying what the risks are and how to remedy them. Methods of estimating project management risk

• Role of business analyst in a risk management process

Request Full Agenda

Trainers

Dr. Malcolm Ross

Generapharm

CEO

Dr. Ross has over 35 years experience in the Generics Industry, the last 15 being at corporate level. He has been intimately involved in strategic planning, pipeline management and related activities. His early industrial experience with Teva and Taro were directed primarily to the US markets but later, as President of IPR, a company jointly owned by PAR and Merck Generics, followed by R&D director for Polpharma, his role expanded to include development for the European markets. Technically Malcolm specialized in development, both of formulations and analytical methodologies and holds a number of patents for novel formulations. In 2006 Malcolm moved to Basel and has worked for Novartis in several roles as well as consulting for a wide range of companies on strategic planning and technical matters. He has conducted many training courses throughout Europe and Asia.

Dr. Malcolm Ross

Generapharm

CEO

Dr. Ross has over 35 years experience in the Generics Industry, the last 15 being at corporate level. He has been intimately involved in strategic planning, pipeline management and related activities. His early industrial experience with Teva and Taro were directed primarily to the US markets but later, as President of IPR, a company jointly owned by PAR and Merck Generics, followed by R&D director for Polpharma, his role expanded to include development for the European markets. Technically Malcolm specialized in development, both of formulations and analytical methodologies and holds a number of patents for novel formulations. In 2006 Malcolm moved to Basel and has worked for Novartis in several roles as well as consulting for a wide range of companies on strategic planning and technical matters. He has conducted many training courses throughout Europe and Asia.

Hanna Hanć (MBA, PMP)

CEO

Qualified andexperienced in business management, consulting and project management (MBA,PMP). Hanna is a business management consultant, having a considerable experience in companies undergoing restructuring, particularly as a result of privatization. Although born in Poland her international experience includes having worked in Spain, Argentina, Luxembourg, Scandinavian countries and Russia. Hanna worked in pharmaceutical production including R&D and API, creative sector – including activities performed “pro public bono”, as well as education and trainings development. Working as a professional in project portfolio management – her major achievement in the field was an introduction of portfolio management processes, organization and IT supporting tools set up in the Polpharma group, the largest pharmaceutical company in Poland (product portfolio adjustment to European Union standards and regulations, including R&D processes).

Hanna Hanć (MBA, PMP)

CEO

Qualified andexperienced in business management, consulting and project management (MBA,PMP). Hanna is a business management consultant, having a considerable experience in companies undergoing restructuring, particularly as a result of privatization. Although born in Poland her international experience includes having worked in Spain, Argentina, Luxembourg, Scandinavian countries and Russia. Hanna worked in pharmaceutical production including R&D and API, creative sector – including activities performed “pro public bono”, as well as education and trainings development. Working as a professional in project portfolio management – her major achievement in the field was an introduction of portfolio management processes, organization and IT supporting tools set up in the Polpharma group, the largest pharmaceutical company in Poland (product portfolio adjustment to European Union standards and regulations, including R&D processes).

Tour info

Testimonial

Price per Delegate (EUR)

2295.00
Register now

Request Full Agenda

For the detailed agenda with a full breakdown of the individual sessions fill out this form.

Thank you! We will verify your request and contact you from this number: +420 223 014 960
Oops! Something went wrong while submitting the form. Please Contact us and we will process your request.

Contact us

Lydia Makori

l.makori@symmetric.events
+421 222 200 543